V
Overview
VIVIO Health uses patient-specific data to guide specialty drug decisions for individuals, not populations. Its product, VIVIO Precision Care, analyzes real-world outcomes to identify which specialty therapies will work and be cost-effective for a patient, addressing high-cost, low-effectiveness treatments and the pharma-centric model. It differs from competitors by focusing on real-world, individual-level data to align drug choices with patient outcomes rather than policy or opinion, reducing supply chain waste. The goal is to improve patient outcomes while lowering total costs for self-insured employers, typically saving 25-35% of spend.
Work here?Claim your company
Simplify's Take
What believers are saying
- June 2026 peer-reviewed data strengthens payer and health-system sales conversations.
- April 2026 advisory-board hires Javed Butler and Biykem Bozkurt add cardiology credibility.
- Expanded website, clinical evidence, and over 40,000 screened patients support commercialization.
What critics are saying
- Ventric Health still sells only in the U.S., limiting reimbursement and growth.
- Physicians can bypass Vivio with echocardiograms and biomarkers, compressing adoption.
- If 2026 guideline enthusiasm fades, Vivio becomes a niche workflow gadget.
What makes VIVIO Health unique
- Vivio is the only FDA-cleared non-invasive LVEDP diagnostic in primary care.
- Physics-based measurement, not AI, produces real-time results in under five minutes.
- 2026 studies show 92.2% conclusive screening and broader outpatient operational feasibility.
Help us improve and share your feedback! Did you find this helpful?